Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Huntington Bancshares Incorporated (HBAN) vs Novartis AG (NVS) Price & Performance

Huntington Bancshares IncorporatedTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Huntington Bancshares Incorporated vs Novartis AG — how do they compare? Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 8.7× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.04%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Novartis AG for 82 Days on average.

HBANNVS
Market Cap
$31.04B$268.57B
Volume
23,864,1721,532,573
Sector
FinancialsHealth
52-Week High
$19.27$168.62
52-Week Low
$15.02$121.80
Typical Hold Time
52 Days82 Days
Enterprise Value
$49.57B$309.89B
Dividend Yield
4.04%3.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Huntington Bancshares Incorporated

Huntington Bancshares (HBAN) trades at $15.32, up 0.99% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $8.13B and net income of $2.21B, with a P/E of 11.82 and ROE of 9.23%. Recent news highlights an increased prime rate to 7.00% and a revised 2027 earnings outlook due to margin pressures.

Outlook is cautious; analyst consensus is a Buy with a $19.60 price target, but near-term headwinds from higher interest rates and deposit costs pose risks. The stock offers value based on valuation metrics, yet investors should weigh margin pressures against shareholder return initiatives like the $550M buyback plan for 2026.

Novartis AG

Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.

The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HBAN

No sentiment data available yet.

NVS
0% Buy100% Sell
Avg holding period · 82 Days

Top news

Latest headlines on both assets

About Huntington Bancshares Incorporated

Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.

Read more on HBAN →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS →